In a letter submitted to the House Energy and Commerce Subcommittee on Oversight and Investigations for a hearing on challenges implementing value-based and alternative payment models under the Medicare Access and CHIP Reauthorization Act of 2015, AHA encouraged certain statutory and regulatory policies to advance and flexibly implement these models. Recommendations include extending incentive payments; investing in resources and infrastructure to support rural hospitals’ transition to APMs; improving cost measures in the Merit-based Incentive Payment System; and supporting more gradual transitions to risk for certain Medicare Shared Savings Program accountable care organizations.  
 
“One additional factor that has impacted the transition to value-based care has been the longstanding challenges with insufficient reimbursement,” AHA said, including site-neutral payment cuts that have contributed to Medicare’s “chronic failure to cover the cost of caring for its beneficiaries.” The association said it “strongly opposes additional site-neutral payment cuts, which threaten access to care.”  

Related News Articles

Headline
In this conversation, Terry Scoggin, CEO of Titus Regional Medical Center, discusses how the organization designed a system of care to ensure that every…
Headline
An analysis by KFF released last week found that in 2022, Medicare spent 27% ($2,585) more, on average, for individuals covered by Traditional Medicare after…
Headline
A House Dear Colleague letter calling on House leadership to address scheduled Medicaid Disproportionate Share Hospital payment cuts received signatures from…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
In comments Dec. 9 to the Medicare Payment Advisory Commission, the AHA shared its views on physician fee schedule payments, advanced alternative payment model…
Headline
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026.…